The news of Benchmark analyst Bruce Jackson reiterating a Buy rating on Clene and maintaining a $7 price target is positive for the stock. This reaffirms the analyst's confidence in the company's potential, which could lead to increased investor interest and a potential short-term increase in the stock price.